First-line non-squamous NSCLC

On the current first-line standard, 92.5% of patients with advanced non-squamous lung cancer have progressed or died within five years.1

Lung cancer kills 1.8 million people a year worldwide.2

The most powerful immunosuppressive pathway in cancer has been off limits for twenty years. We think that ends now.

Please note: Trevalis Labs operates in a stealth capacity.

We read what comes in and answer where we can. Nothing you send is used for anything but a reply. Privacy policy.